|

Regorafenib Clinical Trials

22 actively recruiting trials across 4 locations

Also known as: BAY 73-4506, Closed cohort, Regonix, Stivaga, Stivagra +3 more

Pipeline

Phase 2: 15Phase 3: 1Phase 1/2: 2Phase 2/3: 2

Top Sponsors

  • Fudan University4
  • University of Miami2
  • Peking University Cancer Hospital & Institute2
  • Centre Hospitalier Universitaire de Besancon2
  • Ze-yang Ding, MD1

Indications

  • Cancer22
  • Liver Cancer7
  • Liver Disease5
  • Metastatic Colorectal Cancer3
  • Hepatocellular Carcinoma Non-resectable2

Other16 trials

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Phase 2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Phase 1/2
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Phase 2
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Phase 2
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Phase 2
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Phase 2
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
Phase 3
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Phase 2
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Phase 2/3
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
Phase 2
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama2 trials

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

University of Alabama at Birmingham

Phase 2/3
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Miami, Florida2 trials

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

University of Miami

Phase 2
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

University of Miami

Phase 2

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Cleveland, Ohio1 trial

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.